Psoriasis (Auckland, N.Z.)最新文献_第6页

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. 治疗中重度斑块型银屑病和银屑病关节炎的新治疗方案:评估比美珠单抗及其治疗潜力

Psoriasis (Auckland, N.Z.) Pub Date : 2019-05-24 eCollection Date: 2019-01-01 DOI: 10.2147/PTT.S179283

Andrea Chiricozzi, Clara De Simone, Barbara Fossati, Ketty Peris

引用次数: 13

Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India. 聚焦伊托珠单抗治疗银屑病-来自印度的最新观点。

Psoriasis (Auckland, N.Z.) Pub Date : 2019-05-03 eCollection Date: 2019-01-01 DOI: 10.2147/PTT.S154073

Leelavathy Budamakuntla, H V Shree-Lakshmi, Akshi Bansal, Shankar Kumar Venkatarayaraju

{"title":"Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India.","authors":"Leelavathy Budamakuntla, H V Shree-Lakshmi, Akshi Bansal, Shankar Kumar Venkatarayaraju","doi":"10.2147/PTT.S154073","DOIUrl":"10.2147/PTT.S154073","url":null,"abstract":"Psoriasis is a chronic, debilitating, immune-mediated, systemic inflammatory disease affecting mainly skin, nails, and joints. Several therapeutic modalities are available depending on the severity of the disease. Long-term use of these drugs results in unwanted effects and toxicities. Recently, itolizumab, a humanized monoclonal immunoglobulin G1 antibody to CD6, has shown appreciable clinical effects and safety profile in patients with moderate-to-severe chronic plaque psoriasis. A literature search was conducted using the keywords \"anti-CD6\", \"psoriasis\", \"phase trials\", \"case series\", and \"case reports\". The data from all studies conducted in India on efficacy of itolizumab in psoriasis and published before September 2017 were collected. This article provides an overview of the clinical data obtained in these published articles. Itolizumab has immunomodulatory and anti-inflammatory effects. It is efficacious and provides a good duration of remission, and hence represents a new biological agent that could be added to the therapeutic armamentarium of psoriasis.","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"9 ","pages":"19-27"},"PeriodicalIF":0.0,"publicationDate":"2019-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S154073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37264200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Increased dermal expression of chromatin-associated protein HMGB1 and concomitant T-cell expression of the DNA RAGE in patients with psoriasis vulgaris. 寻常型银屑病患者真皮层染色质相关蛋白 HMGB1 的表达增加，同时 T 细胞表达 DNA RAGE。

IF 5.2

Psoriasis (Auckland, N.Z.) Pub Date : 2019-02-12 eCollection Date: 2019-01-01 DOI: 10.2147/PTT.S190507

Lisa Strohbuecker, Hans Koenen, Esther van Rijssen, Bram van Cranenbroek, Esther Fasse, Irma Joosten, Andreas Körber, Christoph Bergmann

{"title":"Increased dermal expression of chromatin-associated protein HMGB1 and concomitant T-cell expression of the DNA RAGE in patients with psoriasis vulgaris.","authors":"Lisa Strohbuecker, Hans Koenen, Esther van Rijssen, Bram van Cranenbroek, Esther Fasse, Irma Joosten, Andreas Körber, Christoph Bergmann","doi":"10.2147/PTT.S190507","DOIUrl":"10.2147/PTT.S190507","url":null,"abstract":"Purpose: Psoriasis vulgaris (PV) is an autoimmune-related chronic inflammatory disease of the skin, with both vascular and metabolic effects. Aggravating factors have been identified that initiate and maintain inflammation, including expression of Th1-, Th17-, and Th22-cell derived cytokines. Recently, we showed that the evolutionarily ancient and highly conserved damage-associated molecular pattern molecule \"high mobility group box 1 (HMGB1)\" is significantly increased in the serum of PV patients with disease progression and is decreased under standard therapies.Materials and methods: To better understand the role of HMGB1 in the pathogenesis of PV, we recruited 22 untreated psoriatic patients with either mild or severe disease, defined by the Psoriasis Area Severity Index. We assessed HMGB1 and receptor for advanced glycation end products (RAGE) expression in the skin by immunohistochemistry and analyzed the immune-phenotype of Treg and Th17 cells by flow cytometry.Results: We found increased staining for HMGB1 in the dermis of psoriatic plaques in comparison to uninvolved skin of patients with PV. In addition, the major histocompatibility complex class III-encoded DNA and HMGB1 RAGE, induced by HMGB1, were highly expressed on psoriatic CD8+ T cells and CD4+ Treg. High expression of HMGB1 in the lesional skin was associated with even higher expression of its receptor, RAGE, on the cell surface of keratino-cytes in patients with severe PV.Conclusion: The presence of HMGB1 and RAGE signaling may impact orchestration of chronic inflammation in PV which might have implications for Treg and Th17 cells.","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"9 ","pages":"7-17"},"PeriodicalIF":5.2,"publicationDate":"2019-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/9d/ptt-9-007.PMC6385765.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37207171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Type 2 diabetes and psoriasis: links and risks. 2型糖尿病和牛皮癣:联系和风险。

Psoriasis (Auckland, N.Z.) Pub Date : 2019-01-17 eCollection Date: 2019-01-01 DOI: 10.2147/PTT.S159163

Jesper Grønlund Holm, Simon Francis Thomsen

引用次数: 24

Psoriasis and sexual dysfunction: links, risks, and management challenges. 银屑病与性功能障碍：联系、风险和管理挑战。

Psoriasis (Auckland, N.Z.) Pub Date : 2018-12-10 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S159916

Gleison V Duarte, Humberto Calmon, Gabriela Radel, Maria de Fátima Paim de Oliveira

引用次数: 0

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. 聚焦于瑞桑单抗及其治疗斑块型银屑病的潜力:迄今为止的证据。

Psoriasis (Auckland, N.Z.) Pub Date : 2018-11-13 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S165943

Álvaro Machado, Tiago Torres

{"title":"Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date.","authors":"Álvaro Machado, Tiago Torres","doi":"10.2147/PTT.S165943","DOIUrl":"https://doi.org/10.2147/PTT.S165943","url":null,"abstract":"Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients' quality of life. Several highly specific treatments have been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 inhibitor (ustekinumab), and most recently IL-17 inhibitors. Risankizumab is a monoclonal antibody which targets IL-23p19 without binding IL-12. This novel therapeutic approach is expected to have advantages over the recently approved anti-IL-17 agents, such as the avoidance of Candida infections and neutropenia. In addition, unlike ustekinumab, the selective inhibition of IL-23 may preserve IL-12-dependent functions such as protection against infections and tumor immune surveillance. Risankizumab showed an excellent efficacy when compared to placebo and ustekinumab, with higher Psoriasis Area Severity Index (PASI) 75, PASI 90, and PASI 100 rates, along with a convenient every 12-week maintenance dosing regimen. Overall, risankizumab was well tolerated and the most common adverse event was upper respiratory tract infection. In the near future, further data will be available not only in psoriasis but also in Crohn's disease and psoriatic arthritis fields. Head-to-head trials comparing risankizumab with other IL-23 inhibitors and with IL-17 inhibitors will be crucial to reveal the role of risankizumab in the treatment of psoriasis.","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"8 ","pages":"83-92"},"PeriodicalIF":0.0,"publicationDate":"2018-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S165943","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36754345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Secukinumab in the treatment of psoriasis: patient selection and perspectives. Secukinumab治疗牛皮癣:患者选择和观点。

Psoriasis (Auckland, N.Z.) Pub Date : 2018-10-17 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S146004

Eric J Yang, Kristen M Beck, Wilson Liao

引用次数: 23

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. 医师整体评估和体表面积组合工具是银屑病面积和严重程度指数评估银屑病的简单替代方案:来自原始和PRESTA的事后分析。

Psoriasis (Auckland, N.Z.) Pub Date : 2018-10-08 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S169333

Jessica A Walsh, Heather Jones, Lotus Mallbris, Kristina Callis Duffin, Gerald G Krueger, Daniel O Clegg, Annette Szumski

{"title":"The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA.","authors":"Jessica A Walsh, Heather Jones, Lotus Mallbris, Kristina Callis Duffin, Gerald G Krueger, Daniel O Clegg, Annette Szumski","doi":"10.2147/PTT.S169333","DOIUrl":"https://doi.org/10.2147/PTT.S169333","url":null,"abstract":"Background: The product of Physician Global Assessment and Body Surface Area (PGA × BSA) is a new outcome measure for psoriasis severity and response to therapy. The objective of this study was to evaluate PGA × BSA as an alternative to Psoriasis Area and Severity Index (PASI) for psoriasis assessments.Methods: The relationship between PASI and PGA × BSA was assessed in a post hoc analysis of pooled data from the PRISTINE (NCT00663052) and PRESTA (NCT00245960) trials in patients with moderate-to-severe psoriasis who received etanercept 50 mg/week. Data were analyzed using Spearman and intra-class correlation coefficients, effect sizes, scatterplots, Bland-Altman plots, and Kappa statistics.Results: Spearman correlations at baseline, week 12, and week 24 were strong for PGA × BSA versus PASI (r=0.78, 0.87, and 0.90, respectively; all P<0.0001) as were intra-class correlations (0.76 [95% confidence interval 0.73-0.80], 0.80 [0.76-0.83], and 0.85 [0.82-0.87], respectively). The effect size was -1.53 for PASI and -0.94 for PGA × BSA (baseline to week 24). Scatterplots and Bland-Altman plots detected a trend across the range of measurement. Kappa statistics (at 12 and 24 weeks) between PASI50/75/90 and 50/75/90% improvement in PGA × BSA showed good agreement (0.58-0.69 at week 12 and 0.63-0.67, respectively; all P<0.0001). At baseline, the Spearman correlation coefficients were 0.96, 0.51, 0.19, and 0.17 for PGA × BSA versus BSA, PGA, Patient Global Assessment, and Dermatology Life Quality Index, respectively (all P<0.001).Conclusion: PGA × BSA has advantages over PASI for measuring moderate-to-severe psoriasis; it is intuitive, sensitive, and easy to use.","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"8 ","pages":"65-74"},"PeriodicalIF":0.0,"publicationDate":"2018-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S169333","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36588165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Evaluation of ADA activity as a potential marker of disease severity in psoriasis patients. 评估作为银屑病患者疾病严重程度潜在标志的 ADA 活性。

Psoriasis (Auckland, N.Z.) Pub Date : 2018-09-04 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S174119

Seraj Ahmed Khan, Sudha Agrawal, Nirmal Baral, Madhab Lamsal

{"title":"Evaluation of ADA activity as a potential marker of disease severity in psoriasis patients.","authors":"Seraj Ahmed Khan, Sudha Agrawal, Nirmal Baral, Madhab Lamsal","doi":"10.2147/PTT.S174119","DOIUrl":"10.2147/PTT.S174119","url":null,"abstract":"Background: Psoriasis is a dermatological disorder with a multifactorial origin and is associated with many biochemical and immunological changes.Purpose: This study aimed to examine the association of serum ADA activity, uric acid (UA), and high-sensitivity CRP (hs-CRP) with psoriasis and the role of ADA in disease severity.Materials and methods: In this comparative cross-sectional study, 50 clinically and histopathologically diagnosed psoriasis patients and 50 age- and sex-matched healthy controls were enrolled. Blood samples were taken and analysis of the biochemical parameters was performed according to Giuisti and Galanti method, uricase and ELISA technique for ADA activity, UA, and hs-CRP, respectively. The severity of the disease was scored according to Psoriasis Area and Severity Index (PASI). Statistical analysis of differences within and between the study groups was carried out using the Student's t-test, one-way post hoc ANOVA, and Pearson's correlation. Linear regression was used to establish the independent association of ADA with disease severity.Results: The serum ADA activity, UA, and hs-CRP levels of the psoriatic patients were found to be significantly higher (P<0.001). hs-CRP was positively correlated with ADA and UA in patients (P<0.001). There was no significant difference in total cholesterol, low-density lipoprotein, and triacylglycerol in psoriasis patients, whereas we noted a decreased high-density lipoprotein level in psoriasis patients as compared to controls. Linear regression showed that ADA was independently associated with the disease severity and was statistically significant (P<0.001).Conclusion: ADA activity was positively and significantly associated with the severity of psoriasis, therefore, it could be suggested as a marker for disease severity in psoriasis patients.","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"8 ","pages":"59-63"},"PeriodicalIF":0.0,"publicationDate":"2018-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/88/ptt-8-059.PMC6130266.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36505191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. tildrakizumab-asmn治疗中重度斑块型银屑病的概况:迄今为止的证据。

Psoriasis (Auckland, N.Z.) Pub Date : 2018-08-29 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S146640

Kristen M Beck, Isabelle M Sanchez, Eric J Yang, Wilson Liao

引用次数: 13